New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:20 EDTEWEdwards Lifesciences reports positive data on Sapien 3 valve
Edwards Lifesciences announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia. The presentation concluded that outcomes at 30 days were excellent. Transfemoral SAPIEN 3 implantation was associated with a very low mortality of 2.1%, a stroke rate of 1.0%, and very few access-site complications.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:58 EDTEWEdwards Lifesciences price target raised to $179 from $157 at Stifel
Subscribe for More Information
07:46 EDTEWEdwards Lifesciences price target raised to $178 from $160 at Canaccord
Subscribe for More Information
07:43 EDTEWEdwards Lifesciences price target raised to $185 from $155 at Leerink
Subscribe for More Information
07:23 EDTEWEdwards Lifesciences price target raised to $168 from $155 at JPMorgan
Subscribe for More Information
July 28, 2015
16:30 EDTEWEdwards Lifesciences sees Q3 EPS 92c-$1.00, consensus 98c
Sees Q3 revenue $580M-$620M, consensus $587.06M.
16:28 EDTEWEdwards Lifesciences raises FY15 EPS view to $4.30-44.40, consensus $4.28
Backs FY15 revenue view $2.3B-$2.5B, consensus $2.41B
16:26 EDTEWEdwards Lifesciences reports Q2 EPS $1.13 , consensus $1.05
Subscribe for More Information
15:21 EDTEWNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use